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Analyzing metabolites (small molecules <1 kDa) in body fluids such as urine and plasma using 
various spectroscopic methods provides information on the metabotype (metabolic phenotype) 
of individuals or populations, information that can be applied to personalized medicine or public 
healthcare.A major challenge for 21st century medi-
cine is to understand the relationships 
and interactions between genetic varia-
tions and environmental triggers of dis-
ease (Nicholson, 2006). In response to 
this challenge, systems biology powered 
by genomics, proteomics, bioinformat-
ics, and now metabolomics and metabo-
nomics (Box 1), is providing a new logical 
framework to elucidate disease etiol-
ogy and to uncover latent connections 
between seemingly disparate disease 
states (Loscalzo et al., 2007). In particu-
lar, genome-wide association studies 
(GWAS) enable genetic features to be 
linked to many pre-disease conditions 
(Kruglyak, 2008). But GWAS can explain 
only a small proportion of incidence 
variation and may not translate between 
different populations—for example, hav-
ing two copies of an FTO gene variant 
is associated with significantly higher 
levels of obesity and type 2 diabetes in 
Western populations but not in the Han 
Chinese (Li et al., 2008a). Furthermore, 
the relationships between individual 
genomic and phenotypic variations in 
response to drug treatment is still poorly 
understood, and it is unlikely that genetic 
information alone will be able to direct 
personalized drug therapy.
The metabotype or metabolic pheno-
type (Box 1) provides a readout of the 
metabolic state of an individual and is 
the product of genetic and environmen-
tal (diet, lifestyle, gut microbial activity) 
contributions under a particular set of 
conditions (Nicholson, 2006). Analyzing 
metabolites (small molecules <1 kDa) in 
body fluids such as urine and plasma 
using various spectroscopic methods 
provides knowledge of the metabotype. 
Such metabolic profiles provide infor-
mation that cannot be obtained directly 
from the genotype, gene expression pro-
files, or even the proteome of an individ-
ual. These metabolic profiles provide a 
top-down “systems level” readout of the 
biochemistry, physiological status, and 
environmental exposure of individuals 
and populations that can be exploited 
in personalized medicine and public 
healthcare (Nicholson, 2006). Metabo-
lism-driven approaches should prove 
highly tractable as they combine the 
gathering of systemic information based 
on minimally invasive analysis with high-
throughput capabilities.
Metabolome Variation and Metabolic 
Profiling
Factors such as gender, age, diet, gut 
microbiota, physical activity, latent dis-
ease, medication, hormone, and stress 
levels modify the metabotypes of both 
individuals and populations (Figure 1), 
and hence the prevalence and risk of 
disease (Nicholson, 2006; Daviglus et 
al., 2004; Li et al., 2008b). Metabolome-
wide association studies (MWAS) have 
the capacity to link human metabotype 
variations to disease risk factors in the 
general population (Holmes et al., 2008). 
Xenobiotics such as plasticizers, food 
preservatives, pesticides, and plant 
secondary metabolites (caffeine, fla-
vanoids, phytoestrogens) also contrib-
ute to metabotype variations as does gut 
Box 1. Glossary
Conditional metabolic phenotype: A characteristic metabolite profile reflecting the host 
genome and its interaction with environmental factors, diet, and the gut microbiome. 
Co-metabolite and co-metabolome: Compound or set of compounds derived from interac-
tions of more than one genome in symbiotic systems. 
Metabolome: A quantitative description of all endogenous low-molecular-weight compo-
nents (<1 kDa) in a biological sample such as urine or plasma. Each cell type and biological 
fluid has a characteristic set of metabolites that reflects the organism under a particular set 
of environmental conditions and that fluctuates according to physiological demands. The 
metabolome can be divided into the primary metabolome (controlled by the host genome) and 
the co-metabolome (dependent on the microbiome). 
Metabonome: Theoretical combinations, sums, and products of the interactions of multiple 
metabolomes (genome, symbiotic, parasitic, environmental, and co-metabolic) in a complex 
system. 
Metabonomics: The quantitative measurement over time of the metabolic responses of an 
individual or population to drug treatment or other intervention. 
Microbiome: The consortium of microorganisms, bacteria, protozoa, and fungi that live com-
mensally or symbiotically with a host. 
Pharmacometabonomics: Prediction of the quantitative outcome of a drug intervention in an 
individual based on a pre-dose mathematical model of their metabolic state. 
Xenometabolome: Characteristic profile of nonendogenous compounds (drugs and their 
metabolites, pollutants, dietary components, herbal medicines) in a biofluid.714 Cell 134, September 5, 2008 ©2008 Elsevier Inc.
Figure 1. Interactions between Genes and the Environment and Their Effects on Health
Metabolic phenotypes (metabotypes) can be measured by profiling small molecules (<1 kDa) in biofluids 
(usually urine or blood) by spectroscopic techniques such as NMR. Metabolic phenotypes are influenced 
by intrinsic and environmental factors that determine health status and disease risk of an individual or 
group. Measuring and modeling the profile of all metabolites (metabolome) in an individual may provide 
insights into disease risk factors and etiology, information that could be used for personalized medicine.microbiome activity through the produc-
tion of co-metabolites (Li et al., 2008b; 
see Essay by Turnbaugh and Gordon, 
page 708 of this issue). The composition 
of the microbiome (Box 1) has an impact 
on a variety of disorders from intestinal 
disease to obesity and cancer. Under-
standing variation of the co-metabolome 
(Box 1) will shed light on how an imbal-
ance in our microbiota may contribute to 
disease.
Most analytical platforms for meta-
bolic profiling are based on spectro-
scopic techniques, e.g., nuclear mag-
netic resonance (NMR) spectroscopy 
or mass spectrometry (often combined 
with chromatographic separation), to 
permit extensive and rapid analysis of 
small molecule metabolites, generally 
with minimal sample preparation (Nich-
olson et al., 2002). These approaches 
provide relatively high-throughput analy-
ses at low cost per sample. Multiparam-
eter datasets containing quantitative 
information on a comprehensive range of 
classes of small molecules can be pro-
duced, often in a nontargeted manner. 
Given the complexity and high-density 
nature of the spectral data, many com-
puter-based preprocessing and multi-
variate modeling techniques have been 
developed to facilitate the analysis and 
interpretation of these data, in terms of 
the response of an organism to physio-
logical or pathological events; such bio-
informatics techniques can also be used 
to probe gene-environment interactions. 
Mathematical modeling of metabolic 
data enables diagnostic characteriza-
tion allowing identification of potential 
biomarkers, which may contribute to 
a better understanding of pathological 
processes and potentially to the elucida-
tion of new drug targets (Nicholson et al., 
2002).
Discovery of new metabolic biomark-
ers using untargeted metabolic profiling 
could be translated into clinical tools for 
application to personalized medicine. For 
example, we have demonstrated proof-
of-principle of pharmacometabonomics 
(Box 1), in which a mathematical model of 
a group of pre-treatment metabolite pro-
files in rats was used to predict post-drug 
interventional outcomes such as toxicity 
and metabolism of the xenobiotic itself 
(Clayton et al. 2006). Human variability 
is greater than that of experimental ani-
mals and this poses problems as well as 
advantages for modeling, but in principle 
the greater the variation in the metabolic 
starting point the greater the variation in 
resulting observed responses. Clearly, in 
a clinical setting, the complex analytical 
instrumentation used in the discovery 
phase of this type of work would not be 
appropriate or affordable for the mea-
surement of these markers in patients. 
Implementation of this type of monitor-
ing will depend on evolving technolo-Cell 134, gies such as “lab-on-a-chip” methods, 
sensors and electronic “noses,” which 
can detect complex molecular finger-
prints (Westhof et al. 2007) that can be 
tuned to detect specific biomarkers (or 
pathways) rather than providing compre-
hensive metabolic profiles. Ultimately, 
the goal is to have handheld “intelligent” 
devices in the clinic, possibly incorpo-
rating microfluidics, that would detect 
selected proteins, mRNAs and metab-
olites simultaneously in a pin-prick of 
blood. An emerging area that illustrates 
how this might be achieved is in breath 
analysis using ion mobility spectrometry 
(IMS), which has shown promise for the 
diagnosis of infections, lung cancer and 
sarcoidosis based on detecting a range 
of low molecular weight volatile metabo-
lites in exhaled breath (Westhof et al., 
2007).
Another potential strategy is to mea-
sure the chiroptical properties of metab-
olites, an interesting approach given that 
different organisms use different forms 
of optically active isomers. Indeed, sym-
biotic organisms including man contain 
both L- and D-forms of amino acids 
reflecting their human and gut microbial 
sources. Thus “chiral metabonomics” 
using chiroptical spectroscopy or chiral 
chromatographic derivitization meth-
ods can be used to differentiate small 
molecules originating from mammalian 
and microbial metabolism, potentially 
helping to elucidate how such symbi-
otic interactions may go awry in intes-
tinal diseases. For example, L-lactate 
is a mammalian product of anaerobic 
metabolism, but gut bacteria produce 
excessive D-lactate in many gastroin-
testinal disorders causing systemic aci-
dosis that cannot be detected with the 
standard lactate dehydrogenase assay, 
which only detects the L-lactate stereoi-
somer. Methods designed to quantitate 
chiral metabolic components will help to 
deconvolute human and symbiont con-
tributions to the metabotype and their 
relative importance in the etiology of the 
condition or response under study.
Applying a Systems Biology 
 Approach to Medicine
Systems biology is providing many new 
tools to describe, model, and visualize 
the integrated action of regulatory net-
works at all levels of biological organiza-September 5, 2008 ©2008 Elsevier Inc. 715
tion (Loscalzo et al., 2007). In “top-down” 
systems biology we study how biocom-
partments (subcellular, cellular, tissue, 
organ) interact in space and time using 
minimally invasive methods that capture 
the properties of systemic homeostasis 
and its dysregulation (Nicholson, 2006). 
The efficient integration of “omics” data 
and platform outputs via bioinformatics 
should provide a deeper understanding 
of multilevel connections including gene-
gene and gene-environment interactions 
involved in disease development. The 
next decade will see the translation of 
these tools and approaches into predic-
tive and preventive “systems medicine.”
By extracting lists from gene expres-
sion profiles and metabolic profiles 
associated with disease or therapeutic 
intervention, disparate biological events 
can be connected. Several approaches 
have been applied to link genotypes and 
phenotypes in animal models. Exam-
ples include reverse genetics, in which 
a single gene is ablated and the pheno-
typic consequences ascertained, and 
forward genetics, which exploits subtle 
allelic variation relying on identification 
of mutant strains (and underlying genes) 
from the phenotype. Of particular inter-
est are methods that investigate gene-
gene interactions directly by analyzing 
and interpreting microarray expression 
data against a background of traditional 
genetic mapping techniques to estab-
lish associations between quantitative 
trait loci and expression data (eQTLs). 
Three susceptibility genes for obesity 
were identified by an eQTL approach that 
predicted transcriptional responses to a 
single gene perturbation in mice (Schadt 
et al., 2005). This principle was subse-
quently extended to the use of metabolic 
profiles (mQTL) as the basis for mapping 
loci associated with quantitative changes 
in the plasma of a rat strain susceptible to 
type 2 diabetes (Dumas et al., 2007). An 
alternative approach to forward genetics 
has recently been proposed that involves 
identification of gene networks that are 
perturbed by susceptibility loci that may 
lead to the development of disease. This 
approach allows the emergent properties 
of gene relationships to be discovered 
(at least in experimental animals) and the 
validation of new genes associated with 
disease risk such as those associated 
with obesity (Chen et al., 2008).
Tools for modeling metabolic networks 
include those in which nodal architec-
tures (corresponding to genes, gene 
products, proteins, or phenotypes) are 
connected to demonstrate interactions 
between those nodes. More sophisti-
cated approaches using hierarchical 
modularity network strategies reflect the 
clustering of nodes and interconnection 
probabilities (Loscalzo et al., 2007). An 
alternative approach to integrating mul-
tiple omics datasets is to coanalyze the 
disparate matrices to identify those data 
that co-vary and those that are unique. 
It is important to elucidate how different 
levels of cellular nanomachinery interact 
in space and time to control metabolism 
and how they are disrupted in disease. A 
variety of advanced mathematical tools 
including linear projection or Bayes-
ian (conditional probabilistic) methods 
with bidirectional orthogonal filters (to 
remove unwanted noise components 
in the data) can be used to identify co-
variation between metabolite profiles 
and transcriptomic, proteomic, or meta-
genomic data matrices and so give new 
insight into multilevel interactions in 
whole organisms and how they relate to 
disease (Nicholson, 2006).
Predicting the Outcome of  
Therapeutic Interventions
A key goal of modern medicine is to 
develop personalized therapies tailored 
to an individual’s biology. Patient strati-
fication based on biology (genetic and/
or phenotypic) is usually viewed in terms 
of maximizing drug safety and effi-
cacy. Individuals respond differently to 
therapeutic interventions, and adverse 
drug reactions are a cause for concern, 
especially idiosyncratic toxicity that is 
revealed when large populations are 
exposed to new therapeutics. Variations 
among individuals in response to thera-
pies are influenced by differences in the 
conditional metabolic phenotype (Box 1). 
In the mathematical modeling of these 
interindividual variations, the conditional 
metabolic phenotype can be thought of 
as a starting point (pretreatment) for an 
individual in a conceptual multivariate 
metabolic space that reflects the com-
bination of many physical, chemical, 
genetic, and environmental influences. 
It is this starting position (irrespective 
of relative contributions of the individual 
“vector” components) that determines 
the outcome of an intervention. If the 
factors that predispose individuals to 
such idiosyncratic events could be deter-
mined, then at-risk individuals could be 
screened out of a patient population 
helping to retain pharmaceuticals that 
are of value to the majority of patients.
Most personalized approaches to 
drug treatment so far have been based 
on measuring genotype variation and 
polymorphisms in drug metabolizing 
enzymes, such as cytochrome P450 
and N-acetyl transferases (Nebert et 
al., 2003). However, pharmacogenomic 
predictions of drug metabolism and 
toxicity have proved disappointing. We 
have demonstrated a pharmacometa-
bonomic approach to predicting the 
interventional outcome of drugs based 
on mathematical models of pre-dose 
metabolic profiles (Clayton et al., 2006). 
We used a projection-to-latent structure 
(PLS) modeling method to predict liver 
toxicity in rats given a threshold toxic 
dose of the analgesic acetaminophen. 
There was a significant association 
between the pre-dose metabolite profile 
in rat urine and the post-dose outcome 
regarding urinary excretion of acetamin-
ophen metabolites and the severity of 
liver damage. Although preliminary, this 
work shows that there is potential for 
applying pharmacometabonomics non-
invasively for screening human popula-
tions. However, a better understanding is 
needed about the relationships between 
endogenous metabolic status and drug 
metabolism outcomes for a wider range 
of drugs. Ultimately, a judicious mixture 
of pharmacogenomics and pharmaco-
metabonomics will be required to meet 
the personalized healthcare challenge of 
individualized drug therapy.
Molecular Epidemiology and 
Metabolome-Wide Association 
Studies
There is considerable geographical 
metabotype variation between popula-
tion groups linked to ethnicity and life-
style, and this diversity may be closely 
related to disease risk and incidence 
(Holmes et al., 2008). There are well-
documented disparities in genetic back-
ground and diet between geographically 
dispersed populations, and there are 
also regional variations in the incidences 716 Cell 134, September 5, 2008 ©2008 Elsevier Inc.
and concentrations of foreign (xenobi-
otic) metabolites. These xenobiotics also 
contribute to the human metabotype 
and its regional variation in the form of 
the foreign compound profile or xeno-
metabolome (Box 1) of an individual or 
population.
The goal of MWAS is to perform large-
scale metabotyping of populations using 
spectroscopic methods and to relate 
these metabotypes to disease risk fac-
tors. The primary advantage of this 
approach is that the resulting biomark-
ers are genuine metabolic end-points 
and investigations into these pathway 
perturbations may yield new therapeutic 
targets or insights into dietary interven-
tions. This has been demonstrated in 
human populations: a biomarker (for-
mate) identified in the human urinary 
metabolome inversely correlates with 
blood pressure (Holmes et al., 2008). 
Dietary salt intake is strongly linked to 
blood pressure; formate is involved in 
chloride-ion exchange in the kidney via 
the chloride-formate exchanger and the 
SLC26 transporters (a series of intercon-
nected renal ion exchangers involved 
in Na+ and Cl− transport) (Sindic et al., 
2007). In this case, there is a clear con-
nection between the MWAS-derived 
metabolic biomarker and physiological 
evidence pointing to its role in blood 
pressure regulation. Thus, MWAS stud-
ies have the potential to provide new 
insights into disease mechanisms and 
pathophysiology that may ultimately lead 
to new drug targets. As there are many 
hundreds of major epidemiological data 
sets and sample repositories worldwide 
with known long-term outcomes, there is 
a great opportunity to use retrospective 
MWAS to identify new prognostic bio-
markers. Given the complementarity of 
MWAS and GWAS, future molecular epi-
demiological surveys should be able to 
capture both genetic and environmental 
information providing fresh insights into 
changing disease patterns around the 
world and informing personalized and 
public healthcare strategies.
Despite the potential for metabolic phe-
notyping, there remain many challenges 
both analytical and biological. The sheer 
scale of screening required to obtain use-
ful patient stratification information or 
epidemiological insights is still formida-
ble, and there is still no established ana-
lytical exploration strategy. However, we 
do know that a range of techniques both 
“shotgun” and targeted will be required to 
give the metabolome coverage needed 
to discover new biomarker combinations 
for disease risk factors in the general 
population. But these are mainly techni-
cal challenges and will inevitably fall with 
the march of analytical discovery. Per-
haps the greatest challenge of all will be 
data visualization, that is, capturing the 
richness of mathematical models of the 
metabolic phenotypes of vast numbers of 
people so that their biological messages 
can be understood by the medical practi-
tioners of the future.
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